Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus TRIVARIS.
DILACOR XR vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
Calcium Channel Blocker
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination